By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Teznews24
  • जॉब-एजुकेशन
  • इकोनॉमी
  • टेक-ऑटो
  • मनोंरंजन
  • खेल जगत
  • ट्रेवल
  • स्वास्थ्य
Font ResizerAa
Teznews24Teznews24
Search
  • Quick Access
  • Categories
    • इकोनॉमी
    • मनोंरंजन
    • जॉब-एजुकेशन
    • टेक-ऑटो
    • खेल जगत

Top Stories

Explore the latest updated news!
govt planning to expand ab pmjay packages for public hospitals from 23 to 112 nha sources From 23 to 112 Health Packages in Public Hospitals, ETHealthworld

From 23 to 112 Health Packages in Public Hospitals, ETHealthworld

why every cfo should be in goa this weekend etcfo annual conclave 2026 starts tomorrow Redefining the CFO's Role in India's Business Landscape, ETCFO

Redefining the CFO’s Role in India’s Business Landscape, ETCFO

new blood test measures alzheimers progression Revolutionary Blood Test Could Transform Alzheimer's Disease Diagnosis, ETHealthworld

Revolutionary Blood Test Could Transform Alzheimer’s Disease Diagnosis, ETHealthworld

Stay Connected

Find us on socials
248.1k Followers Like
61.1k Followers Follow
165k Subscribers Subscribe
Made by ThemeRuby using the Foxiz theme. Powered by WordPress
Teznews24 > स्वास्थ्य > White Blood Cell DNA Enhances Cancer Detection Accuracy in Blood Tests, ETHealthworld
स्वास्थ्य

White Blood Cell DNA Enhances Cancer Detection Accuracy in Blood Tests, ETHealthworld

admin
Last updated: 2026/11/19 at 7:53 AM
By admin Add a Comment
Share
SHARE

Contents
Join the community of 2M+ industry professionals. Subscribe to Newsletter to get latest insights & analysis in your inbox.All about ETHealthworld industry right on your smartphone!

135981144 White Blood Cell DNA Enhances Cancer Detection Accuracy in Blood Tests, ETHealthworld

Bengaluru: An Indian study has challenged a long-held assumption in blood-based cancer detection, finding that DNA released by white blood cells (WBCs) may strengthen, rather than dilute, tumour-related signals in the bloodstream. The findings could offer new insights into why the sensitivity of blood-based cancer tests varies among patients, including those diagnosed at the same stage of disease.

The four-year study examined CancerSpot, a multi-cancer early detection test developed by Strand Life Sciences, a genomics subsidiary of Reliance Industries. The test combines DNA sequencing with Artificial Intelligence (AI) to identify methylation patterns, or chemical modifications of DNA, that help distinguish cancer-associated fragments from those originating in normal cells.

Recently published in the Proceedings of the National Academy of Sciences (PNAS), the research found that higher levels of circulating cell-free DNA in cancer patients were associated with stronger cancer-related signals and improved detection sensitivity, even among patients at the same stage of cancer.

Conducted across 43 hospitals in India, the study analysed blood samples from 1,480 participants, including patients with 14 types of cancer and healthy individuals. It examined the biological factors influencing the detection of cancer-associated signals in the bloodstream.

The central finding challenges the assumption that an increase in DNA released by white blood cells would make it harder to identify the much smaller fraction originating from tumours. Researchers found that tumour and immune-cell contributions to circulating DNA appeared to increase in synchrony, with tumour-derived signals keeping pace with, and in some cases outpacing, the increase in immune-cell DNA.

The difference was particularly evident in early-stage disease. Among Stage I cancer patients, the detection rate was 52 per cent in those with lower levels of circulating DNA, compared with 85 per cent among those with higher levels. The finding suggests that total cell-free DNA concentration could be an important variable in understanding the sensitivity of blood-based cancer detection tests, alongside conventional tumour staging.

In an independent validation cohort, CancerSpot reported an overall sensitivity of 72 per cent and a false-positive rate of 1.4 per cent. The test also identified the likely tissue or location of cancer in approximately 76 per cent of cases.

The findings could have implications for how emerging multi-cancer early detection technologies are evaluated. Cancer detection studies have traditionally assessed sensitivity according to tumour stage, with early-stage cancers generally more difficult to identify. The research suggests that total circulating DNA levels could provide an additional measure for understanding why detection rates vary between patients at the same stage.

Commenting on the publication, Dr Ramesh Hariharan, CEO, Strand Life Sciences, said, “In early cancer detection, clinical utility depends on walking a tightrope: maximizing sensitivity to catch disease early while minimizing false-positives that lead to unnecessary invasive procedures and patient harm. Achieving that balance requires deep scientific insight and rigorous validation. Having our work published in PNAS attests to the rigor of our science and the quality of our clinical evidence, marking a pivotal milestone in our mission to bring reliable, scalable early detection beyond the current standard-of-care, to India.”

The research comes amid growing interest in blood-based multi-cancer screening technologies, which aim to detect cancer signals through a single blood draw rather than relying exclusively on organ-specific screening methods.

Unlike conventional imaging techniques, which primarily identify tumours based on their size, DNA methylation-based tests look for molecular signals released by tumour cells into the bloodstream. These approaches could potentially complement existing screening pathways, particularly for cancers that currently lack established population-level screening recommendations.

However, such tests are not diagnostic tools and cannot replace established screening methods such as mammography, colonoscopy or low-dose CT scans. A positive result indicates the need for further clinical evaluation through targeted imaging, endoscopy and, where indicated, biopsy. A negative result also does not rule out cancer.

  • Published On Nov 19, 2026 at 12:47 PM IST

Join the community of 2M+ industry professionals.

Subscribe to Newsletter to get latest insights & analysis in your inbox.

All about ETHealthworld industry right on your smartphone!


health barcode White Blood Cell DNA Enhances Cancer Detection Accuracy in Blood Tests, ETHealthworld

Source link

TAGGED: blood cancer detection, CancerSpot test, circulating cell-free DNA, early cancer detection, white blood cell DNA
Share This Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related Stories

Uncover the stories that related to the post!
govt planning to expand ab pmjay packages for public hospitals from 23 to 112 nha sources From 23 to 112 Health Packages in Public Hospitals, ETHealthworld
स्वास्थ्य

From 23 to 112 Health Packages in Public Hospitals, ETHealthworld

new blood test measures alzheimers progression Revolutionary Blood Test Could Transform Alzheimer's Disease Diagnosis, ETHealthworld
स्वास्थ्य

Revolutionary Blood Test Could Transform Alzheimer’s Disease Diagnosis, ETHealthworld

climate change insecticide resistance could threaten malaria eradication murmu Climate Change and Insecticide Resistance Threaten India's Malaria Eradication, ETHealthworld
स्वास्थ्य

Climate Change and Insecticide Resistance Threaten India’s Malaria Eradication, ETHealthworld

maharashtra govt orders regular audits of c section deliveries Maharashtra Government Mandates Audits for C-Section Deliveries to Ensure Maternal Safety, ETHealthworld
स्वास्थ्य

Maharashtra Government Mandates Audits for C-Section Deliveries to Ensure Maternal Safety, ETHealthworld

nppa extends knee implant price cap by two months amid scrutiny of trade margins NPPA Extends Knee Implant Price Cap Amid Industry Scrutiny, ETHealthworld
स्वास्थ्य

NPPA Extends Knee Implant Price Cap Amid Industry Scrutiny, ETHealthworld

fssai seeks scientific evidence on red bull energy drink label issues show cause notice FSSAI Demands Scientific Evidence from Red Bull on 'Energy Drink' Claims, ETHealthworld
स्वास्थ्य

FSSAI Demands Scientific Evidence from Red Bull on ‘Energy Drink’ Claims, ETHealthworld

patient group flags high tb burden despite mortality decline seeks transparency in reporting High Disease Burden Persists Despite Decline in Mortality, ETHealthworld
स्वास्थ्य

High Disease Burden Persists Despite Decline in Mortality, ETHealthworld

fssai action against 6 nutraceutical manufacturers for serious violations FSSAI action against 6 nutraceutical manufacturers for serious violations, ETHealthworld
स्वास्थ्य

FSSAI action against 6 nutraceutical manufacturers for serious violations, ETHealthworld

Show More
teznews24 teznews24
  • Categories:
  • Fashion
  • Travel
  • Sport
  • Adverts

Quick Links

About US

  • Adverts
  • Our Jobs
  • Term of Use
Made by ThemeRuby using the Foxiz theme. Powered by WordPress
Welcome Back!

Sign in to your account

Lost your password?